---
layout: minimal-medicine
title: Antihemophilic Factor (Recombinant) Porcine Sequence
---

# Antihemophilic Factor (Recombinant) Porcine Sequence
### Generic Name
Antihemophilic Factor (Recombinant) Porcine Sequence

### Usage
Antihemophilic factor (recombinant) porcine sequence is specifically indicated for treating bleeding episodes in adults with acquired hemophilia A.  It's crucial to understand that this medication is *not* indicated for treating congenital hemophilia A or von Willebrand disease.  Its use in these conditions is considered off-label and hasn't undergone the same rigorous testing.

### Dosage

**Acquired Hemophilia A:** Dosage depends on the bleeding severity, desired factor VIII levels, and individual patient response.  Plasma factor VIII levels should not exceed 200% of normal (200 units/dL). Patients with antibodies against the medication may require higher doses or more frequent administration.

* **Minor to Moderate Hemorrhage:**  The initial intravenous (IV) dose is typically 200 units/kg to achieve a factor VIII plasma level of 50-100% of normal. Subsequent doses are titrated to maintain the desired factor VIII levels and are administered every 4-12 hours, adjusting the frequency based on clinical response and factor VIII levels.

* **Major Hemorrhage:** The initial IV dose is 200 units/kg to achieve a factor VIII plasma level of 100-200% of normal for acute bleeding, or 50-100% after the acute bleeding is controlled (if needed). Subsequent doses are titrated and administered every 4-12 hours, adjusting frequency as needed. Alternatively, an initial dose of 100 units/kg may be used, with subsequent doses and intervals titrated to maintain desired levels (this is considered off-label dosing).

**Congenital Hemophilia A (Off-Label Use):**  While not approved for this, some clinicians might use it. The initial IV dose is 200 units/kg, with subsequent doses titrated according to factor VIII activity levels and individual patient response.


**Pediatric Dosage:** The safety and efficacy of this medication have not been established in children.

**Dosage Adjustments:** No specific dosage adjustments are provided in the manufacturer's labeling for patients with hepatic (liver) or renal (kidney) impairment.

### Side Effects

* **Common:**  Development of antibodies is a potential complication reported in more than 10% of patients.

* **Less Common but Serious:** Hypersensitivity reactions are possible.

* **Post-Marketing:** Increased factor VIII inhibitors (anamnestic reaction) have been reported after the drug was released to the market.

If any adverse effects occur, consult a healthcare provider immediately.

### How it Works

Antihemophilic factor (recombinant) porcine sequence temporarily replaces the body's inhibited factor VIII. Factor VIII is crucial for blood clot formation. The medication activates factor X, which then converts prothrombin to thrombin. Thrombin, in turn, converts fibrinogen to fibrin, forming a stable blood clot with the help of factor XIII.  In essence, it helps restore the body's natural clotting process.

### Precautions

* **Contraindications:** This medication is contraindicated in patients with life-threatening hypersensitivity reactions to antihemophilic factors (recombinant [porcine sequence]) or any component of the formulation.

* **Increased Risks:** There's an increased risk of hypersensitivity reactions and the formation of antibodies against the porcine factor VIII.

* **Administration:** Administer intravenously at a rate of 1-2 mL/min.  Do not mix with other medications in the same tubing or container.

* **Pregnancy and Lactation:**  This medication falls under Pregnancy Category C. Use during pregnancy is only justified if the benefits clearly outweigh the potential risks to the fetus.  Excretion in breast milk is unknown; caution is advised when administering to nursing mothers.


### FAQs

* **Q: How long does it take to work?** A: The onset of action varies depending on the dose and individual patient response, but effects are generally seen relatively quickly after intravenous administration.  Regular monitoring of factor VIII levels is essential.

* **Q: How is it stored?** A:  Refer to the product labeling for specific storage instructions. Generally, it requires refrigeration.

* **Q: What should I do if I miss a dose?** A:  Contact your doctor or healthcare provider immediately for guidance if a dose is missed, especially if bleeding occurs.

* **Q: Are there any interactions with other medications?** A: No significant interactions are currently reported in the manufacturer's labeling, but always inform your doctor of all medications you are taking.

* **Q: Can I drive while taking this medication?** A:  This depends on your overall health and the severity of your condition. Follow your doctor's advice.

**Disclaimer:** This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Always consult a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The information provided here is based on publicly available sources and may not reflect all possible updates or variations in product information. Always refer to the official prescribing information provided by the manufacturer for the most accurate and up-to-date details.
